The first experience with intraabdominal chemotherapy in patients with disseminated ovarian cancer

Ovarian cancer (OC) is characterized by its late diagnosis, mainly local tumor dissemination within the abdomen and small pelvis, and a relatively high susceptibility to drug therapy . Intraabdominal chemotherapy (CT) allows the higher intraabdominal drug concentrations to be produced as compared to systemic CT and, according to the data of some investigations, improves the results of treatment in a few patients with minimal tumor foci. In this connection, it is urgent to master the procedure of intraperitoneal CT, including to pl ace an intraabdominal port, to elaborate a regimen, and to determine the spectrum of its toxicity and safety.
Subjects and methods. The paper gives the preliminary results of a pilot trial using intraabdominal CT in 8 patients with disseminated OC and fallopian tubes who have undergone optimal-volume surgical interventions in stage 1. All the patients received CT by the scheme: intravenous paclitaxel (135 mg/m 2) on day 1, intraabdominal cisplatin (75 mg/m 2) on day 2, and intraabdominal paclitaxel (60 mg/m 2) on day 8. A total of 6 courses were scheduled.
Results. At the analysis of the results, 5 out the 8 patients received all the scheduled courses of CT, 3 patients continued treatment, including 1 patient in whom the intraabdominal port w as removed after the first course of CT because of significant fibrosis along the in traabdominal catheter, thereafter she continued to be treated by the standard intravenous scheme. Among local toxicity signs, there was a preponderance of grades 1–2 abdominal pains occurring after the intraabdominal administrations of chemotherapy preparations. Systemic toxicity, including hematological one, was moderate; in any cases it did not cause life-threatening complications or lead to the increase of course intervals or to the refusal of intraabdominal CT. At a median follow-up of 10.2 months (range 1.9–24.7 months or more), one patient w as found to have disease progression 12 months of therapy termination.

1. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2008 г. Вестн РОНЦ им. Н.Н. Блохина 2010;21 (1, прил. 1):57, 92.

2. Ozols R.F., Bundy B.N., Greer B.E. et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected III stage, ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;3194 –200. 3. Neijt J.P., Engelholm S.A., Tuxen M.K. et al. Exploratory phase III study of paclitaxel and cisplatin vs paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 2000;18:3084–92.

3. Francis P., Rowinsky E., Schneider J. et al. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: A Gynecologic Oncology Group pilot study. J Clin Oncol 1995;13:2961–7.

4. Lopez J.A., Krikorian J.G., Reich S.D. et al. Clinical pharmacology of intraperitoneal cisplatin. Gynecol Oncol 1985;20:1–9.

5. Los G., Mutsaers P.H.A., van der Vijgh W.J.F. et al. Direct diffusion of cisdiamminedichloroplatinum (II)

6. in intraperitoneal rat tumors after intraperitoneal chemotherapy: A comparison with systemic chemotherapy. Cancer Res 1989;49:3380–4.

7. Dedrick R.L., Flessner M.F. Pharmacokinetic problems in peritoneal drug administration: Tissue penetration and surface exposure. J Natl Cancer Inst 1997;89:480–7.

8. Alberts D.S., Liu P.Y., Hannigan E.V. et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996;335:1950–5.

9. Markman M., Bundy B.N., Alberts D.S. et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001;19:1001–7.

10. Armstrong D., Bundy B., Wenzel L. et al. Phase III randomized trial of intravenous cisplatin and paclitaxel versus an intensive regimen of intravenous paclitaxel, intraperitoneal cisplatin, and intraperitoneal paclitaxel in stage III ovarian cancer: a Gynecologic Oncology Group study. N Engl J Med 2006;354:34–43.

11. WHO handbook for reporting results of cancer treatment. Geneva (Switzerland). World Health Organization Offset Publication No 48, 1979.

12. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS, March 31, 2003. Available at: http://ctep.cancer.gov

13. National Cancer Institute. NCI Issues clinical announcement for preferred method of treatment for advanced ovarian cancer. Available at: http://www.cancer.gov/ newscenter/ressreleases/ IPchemotherapyrelease

14. Walker J.L., Armstrong D.A., Huang D.Q. et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian or primary peritoneal cancer. A Gynecologic Oncology Group study. Gynecol Oncol 2006;100:27–32.

15. Levin L., Simon R., Hryniuk W. et al. Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis. J Natl Cancer Inst 1993;85:1732.